08.05.2023 07:30:10
|
EQS-News: APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights
EQS-News: APONTIS PHARMA AG
/ Key word(s): Product Launch
APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights
For the German market alone, APONTIS PHARMA anticipates an annual sales potential of more than EUR 7.0 million in the medium term. In Germany, around 290,000 people are currently taking a loose combination of the two classes of active ingredients contained in the new Single Pill. The market launch of this new Single Pill with EU-wide IP rights is planned for 2027/2028 in Germany, with five further Single Pills with EU-wide IP rights scheduled for market launch in 2026/2027 according to current planning. APONTIS PHARMA is thus currently pursuing the development of six Single Pills with EU-wide property rights. In total, APONTIS PHARMA has announced the medium-term market launch of 15 Single Pills, which will successively complement the existing Single Pill portfolio. At least three additional Single Pills are expected to be launched in 2023. Currently, APONTIS PHARMA has ten approved Single Pills. In view of the accelerated portfolio expansion through contract developments and in-licensing, APONTIS PHARMA is confident to comfortably exceed the announced target of at least 20 Single Pills by 2026. Zentiva is a producer of high-quality and affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 4,800 people and a network of production sites - including flagship sites in Prague, Bucharest, and Ankleshwar - Zentiva strives to be the champion of branded and generic medicines in Europe to better support peoples daily healthcare needs. More than ever, people need better access to high-quality affordable medicines and healthcare. We work in partnership with physicians, pharmacists, wholesalers, regulators, and governments to provide the everyday solutions that we all depend on. APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. APONTIS PHARMA develops, promotes, and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS PHARMA successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europes leading pharmaceutical and chemical regions. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 25,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de. Investor Relations CROSS ALLIANCE communications GmbH
08.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | APONTIS PHARMA AG |
Alfred-Nobel-Str. 10 | |
40789 Monheim | |
Germany | |
E-mail: | ir@apontis-pharma.de |
Internet: | https://apontis-pharma.de/ |
ISIN: | DE000A3CMGM5 |
WKN: | A3CMGM |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1626041 |
End of News | EQS News Service |
|
1626041 08.05.2023 CET/CEST
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu APONTIS PHARMAmehr Nachrichten
Analysen zu APONTIS PHARMAmehr Analysen
Aktien in diesem Artikel
APONTIS PHARMA | 9,96 | 0,00% |